Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status

Urological Research

Volumn 30, Issue 5, 2002, Pages 289-294

  Serafin, Antonio M ^a   Akudugu, John M ^a   Bohm, Lothar ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Androgen status; Chemosensitivity; P53; Prostate cell lines

Indexed keywords

ANDROGEN; ANDROSTANOLONE; COBALT 60; ESTRACYT 3; ESTRAMUSTINE; ETOPOSIDE; PROTEIN P21; PROTEIN P53; VINBLASTINE; VINBLASTINE PCH;

ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG EFFICACY; DRUG RESISTANCE; GENE FUNCTION; HUMAN; HUMAN CELL; IRRADIATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; VIRUS;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRAMUSTINE; ETOPOSIDE; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 0036919918     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-002-0277-y     Document Type: Article

References (47)

1. Baker FL, Spitzer G, Ajani JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C (1986) Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using the cell-adhesive matrix and supplemented medium. Cancer Res 46:1263
2. Bayne CW, Ross M, Donnelly F, Chapman K, Buck C, Bollina P, Habib FK (1998) Selective interactions between prostate fibroblasts and epithelial cells in co-culture maintain the BPH phenotype. Urol Int 61:1
3. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP (1995) Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735
4. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477
5. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL (1997) Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 57:995
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters responses to therapeutic agents. J Clin Invest 104:263
7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AL, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 258:1650
8. Dalton WS (1997) Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34 [Suppl 5]:3
9. WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin. Int J Oncol 15:861
10. El-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817
11. El-Deiry W, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169
12. Eliopoulos AG, Derr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217
13. Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574
14. Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM, Dalton WS (1996) Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66:520
15. Gerson SL, Wilson JK (1995) O6-alkylguanine-DNA alkyl-transferase: a target for the modulation of drug resistance. Hematol Oncol Clin North Am 9:431
16. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P (1995) Establishment and characterization of an immortalised but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol 31A:14
17. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809
18. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 17:3160
19. Kaign ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). J Urol 17:16
20. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y Cossman J (1993) bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251
21. Keshalava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61:6185
22. Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activity by the E6 gene product of human papillomavirus type 16. Nature 380:79
23. Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, Furukawa T, Akiyama S, Ohi Y (1996) Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer 69:488
24. Landowski TH, Gleason-Guzman MC, Dalton WS (1997) Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89:1854
25. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464
26. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807
27. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N (1998) bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52:1085
28. Malkin D (1994) p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta 1198:197
29. May P, May E (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18:7621
30. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW (1997) bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94:2345
31. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391
32. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyl-transferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119
33. Pienta KJ, Lehr JE (1993) Inhibition of prostate cancer cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149:1622
34. Pienta KJ, Naik H, Lehr JE (1996) Effect of estramustine, etoposide, and Taxol on prostate cancer cell growth in vitro and in vivo. Urology 48:164
35. Raffo AJ, Perlman H, Chen M, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438
36. Reed JC (1997) Bcl-2 family proteins: regulators of aopotosis and chemoresistance in hematologic malignancies. Semin Hematol 34: [Suppl 5]:9
37. Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR, Loening S, Soloway M, deKernion JB, Pontes JE, Slack NH, Murphy GP (1980) Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 45:1937
38. Schwab TS, Stewart T, Lehr J, Pienta KJ, Rhim JS, Macoska JA (2000) Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures, The Prostate 44:164
39. 2 block abrogation. Urol Res 29:221
40. Shustik C, Dalton W, Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1
41. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664
42. Somasundaram K, El-Deiry WS (2000) Tumor suppressor P53: regulation and function. Front Biosci 5:424
43. Speicher LA, Barone L, Tew KD (1992) Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433
44. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 21:274
45. Tannock IF (1985) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013
46. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756
47. Werner F, Zölzer F, Streffer C (2001) P53 levels, cell cycle kinetics and radiosensitivity in two SV40 transformed Wi38VA13 fibroblast strains. Sonderb Z Strahlenther Onkol 177:662